Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways

Clinical and Experimental Rheumatology

Volumn 25, Issue 4, 2007, Pages 546-555

  Legendre, Florence ^a   Bogdanowicz, Patrick ^a   Martin, Gregoire ^a   Domagala, Florence ^b   Leclercq, Sylvain ^c   Pujol, Jean Pierre ^a   Ficheux, Herve ^b  

^a UNIVERSITÉ DE CAEN   (France)

^b Negma Lerads Laboratories   (France)

^c Clinique Saint Martin   (France)

Author keywords

Chondrocytes; Interleukin 1; Matrix degrading enzymes; Osteoarthritis; Proliferation; Rhein; Synoviocytes

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ADAMTS 4 PROTEIN; ADAMTS 5 PROTEIN; AGGRECANASE; AGGRECANASE 1; AGGRECANASE 2; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; COLLAGENASE 3; DISINTEGRIN; GELATINASE A; INTERLEUKIN 1; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE; RHEIN; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; SYNOVIOCYTE; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; ANTHRAQUINONES; CARTILAGE, ARTICULAR; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INTERLEUKIN-1; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; METALLOPROTEASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROCOLLAGEN N-ENDOPEPTIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 34648839975     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. PUJOL JP, LOYAU G: Interleukin-1 and osteoarthritis. Life Sci 1987; 41: 1187-98.
2. SHINMEI M, MASUDA K, KIKUCHI T, SHIMORMURA Y: The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol 1989; 18 (Suppl.): 32-4.
3. SANDY JD: A contentious issue findO some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cart2006; 14: 95-100.
4. GOLDRING MB, BIRKEAD L, SANDELL LJ, KIMURA T, KRANE SM: Interleukin-1 suppresses expression of cartilage specific type II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988; 82: 2026-37.
5. CHADJICHRISTOS C, GHAYOR C, KYPRIOTOU M et al.: Sp1 and Sp3 transcription factors mediate interleukin-1β down-regulation of human type II collagen gene expression in articular chondrocytes. J Biol Chem 2003; 278: 39762-72.
6. BENTON HP, TYLER JA: Inhibition of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1988; 154: 421-8.
7. DINARELLO CA: Interleukin-1. Dig Dis Sci 1988; 33: 25S-35S.
8. RÉDINI F, MAUVIEL A, PRONOST S, LOYAU L, PUJOL J-P: Transforming growth factor β exerts opposite effects from Interleukin-1β (IL-1β) on cultured rabbit articular chondrocytes through reduction of IL-1 receptor expression. Arthritis Rheum 1993; 36: 44-50.
9. BOUMEDIENE K, CONROZIER T, MATHIEU P et al. : Decrease of cartilage transforming growth factor-β receptor II expression in the rabbit experimental osteoarthritis - Potential role in cartilage breakdown. 0steoarthritis Cart 1998; 6: 146-9.
10. SERRA R, JOHNSON M, FILVAROFF EH et al.: Expression of a truncated, kinase defective TGF-β type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997; 139: 541-52.
11. LINGETTI M, D'AMBROSIO PL, Di GREZIA F, SORRENTINO P, LINGETTI EA: Controlled study in the treatment of osteoarthritis with diacerhein (Artrodar). Curr Ther Res 1982; 31: 408-12.
12. MARCOLONGO R, FIORAVANTI A, ADAMI S, TOZZI E, MIAN M, ZAMPIERI A: Efficacy and tolerability of diacerhein in the treatment of osteoarthrosis. Curr Ther Res 1988; 43: 878-87.
13. NGUYEN M, DOUGADOS M, BERDAH L, AMOR B: Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994, 37: 529-36.
14. PELLETIER JP, YARON M, HARAOUI B et al.: Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. Arthritis Rheum 2000; 43: 2339-48.
15. DOUGADOS M, NGUYEN M, BERDAH L et al.: Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis. Arthritis Rheum 2001; 44: 2539-47.
16. BRANDT KD, SMITH G, KANG SY, MYERS S, O'CONNOR B, ALBRECHT M: Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cart 1997; 5: 438-49.
17. HWA SY, BURKHARDT D, LITTLE C, GHOSH P: The effect of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. J Rheumatol 2001; 28: 825-34.
18. SMITH GN, MYERS SL, BRANDT KD, MICKLER EA, ALBRECHT ME: Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum 1999; 42: 545-54.
19. TAMURA T, OHMORI K: Diacerein suppresses the increase in plasma nitric oxide in rat adjuvant-induced arthritis. Eur J Pharmacol 2001; 419: 269-74.
20. PUJOL, JP, FÉLISAZ N, BOUMEDIENE K et al.: Effects of diacerhein on biosynthesis activities of chondrocytes in culture. Biorheology 2000; 37: 177-84.
21. YARON M, SHIRAZI I, YARON I: Anti-interleukin-1 effects of diacherein and rhein in human osteoarthritic synovial tissue and cartilage cultures. 0steoarthritis Cart 1999; 7: 272-80.
22. POMARELLI P, BERTI M, GATTI, MOSCONI P: A non-steroidal anti-inflammatory drug that stimulates prostaglandin release. Farmaco 1980; 35: 836-42.
23. FRANCHI-MICHELI S, LAVACCHI L, FRIEDMANN CA, ZILETTI Z: The influence of rhein on the biosynthesis of prostaglandin-like subatances in vitro. J Pharm Pharmacol 1983; 35: 262-4.
24. FÉLISAZ N, BOUMEDIENE K, GHAYOR C et al.: Stimulating effect of diacerein on TGF-β1 and β2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cart 1999; 7: 255-67.
25. RÉDINI F, GALÉRA P, MAUVIEL A, LOYAU G, PUJOL J-P: Transforming growth factor-β stimulated collagen and glycosaminoglycan biosynthesis in cultured rabbit chondrocytes. FEBS Lett 1988; 234: 172-6.
26. SANCHEZ C, MATHY-HARTERT, DEBERG MA, FICHEUX H, REGINSTER J-YL, HENROTIN YE: Effects of rhein on human articular chondrocytes in alginate beads. Biochemical Pharmacology 2003; 65: 377-88.
27. RAJPUROHIT R, HOCH CJ, TAO Z, TEIXEIRA CM, SHAPIRO IM: Adaptation of chondrocytes to low oxygen tension: Relationships between hypoxia and cellular metabolism. J Cell Physiol 1996; 168: 424-32.
28. MARTIN G, ANDRIAMANALIJAONA R, GRASSEL S et al.: Effect of hypoxia and reoxygenation on gene expression and response to interleukin-1 in cultured articular chondrocytes. Arthritis Rheum 2004; 50: 3549-60.
29. LIN S, LI JJ, FUJII M, HOU DX: Rhein inhibits TPA-induced activator protein-1 activation and cell transformation by blocking the JNK-dependent pathway. Int J Oncol 2003; 22: 829-33.
30. BENYA PD, PADILLA SA, NIMNI ME: The progeny of rabbit articular chondrocytes synthesize collagen types I and III and type I trimer, but not type II. Verification by cyanogen bromide peptide analysis. Biochemistry 1977; 16: 865-872.
31. LEGENDRE F, DUDHIA J, PUJOL J-P, BOGDANOWICZ P: JAK/STAT but not ERK1/ ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem 2003; 278: 2903-12.
32. SADOWSKI HB, GILMAN MZ: Cell-free activation of a DNA binding protein by epidermal growth factor. Nature 1993; 362: 79-83.
33. BELLIDO T, BORDA VJC, ROBERTSON P, MANOLAGAS SC: Activation of the Janus kinase/STAT (signal transducers and activator of transcription). Endocrinology 1997; 138: 3666-76.
34. MARTIN G, BOGDANOWICZ P, DOMAGALA F, FICHEUX H, PUJOL J-P: Rhein inhibits Interleukin-1-induced activation of MEK/ERK pathway and DNA binding of NF-κB and AP-1 in chondrocytes cultured in hypoxia: A potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation 2003; 27: 233-46.
35. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
36. LIVAK KJ, SCHMITTGEN TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
37. BOUMEDIENE K, FÉLISAZ N, PUJOL JP: Cell cycle dependent expression of transforming growth factor type I receptor correlates with differential proliferative effects of TGF-β1 in articular chondrocytes. Exp Cell Res 1998; 243: 173-84.
38. LIACINI A, SYLVESTER J, LI WQ, ZAFARULLAH M: Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002; 21: 251-62.
39. BUTTICES; G, QUINONES S, KURKINEN M: The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene. Nucleic Acids Res 1991; 19: 3723-31.
40. PENDAS AM, BALBIN M, LLANO E, JIMENEZ MG, LOPEZ-OTIN C: Structural analysis and promoter characterization of the human collagenase-3-gene (MMP13). Genomics 1997; 40: 222-33.
41. MENGSHOL JA, VINCENTI MP, COON CL, BARCHOWSKY CE: Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun terminal kinase, and nuclear factor kappa B: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000; 43: 801 -11.
42. BOND M, BAKER AH NEWBY AC: Nuclear factor kappa B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999; 264: 561-7.
43. BONDESON J, FOXWELL B, BRENNNAN F, FELDMANN M: Defining therapeutic targets by using adenovirus: Blocking NF-kappa B inhibits both inflammatory mediators. Proc Natl Acad Sci USA 1999; 96: 5668-73.
44. AHMAD M, THEOFANIDIS P, MEDFORD RM: Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha. J Biol Chem 1998; 273: 4616-21.
45. MENDES AF, CARAMONA MM, CARVALHO AP, LOPES MC: Role of mitogen-activated protein kinases and tyrosine kinases on interleukin-1-induced NF-κB activation and iNOS expression in bovine articular chondrocytes. Nitrix Oxide 2002; 6: 35-44.
46. PELLETIER JP, MINEAU F, FERANDES JC, DUVAL N, MARTEL-PELLETIER J: Diacerhein and rhein reduce the interleukin-1 β stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 1998; 25: 2417-24.
47. GLASSON SS, ASKEW R, SHEPPARD B et al.: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644-48.
48. ANDRIAMANALIJAONA R, BAUGÉ C, RENARD E et al.: Comparative effects of two antioxidants, selenomethionine and epigallocatechin-gallate on the catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol 2005; 32: 1958-67.
49. PELLETIER JP, MARTEL-PELLETIER J, ABRAMSON SB: Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237-47.
50. HEDBOM E, HAUSELMANN HJ: Molecular aspects of pathogenesis in osteoarthritis : The role of inflammation. Cell Mol Life Sci 2002; 59: 45-53.
51. BENITO MJ, VEALE DJ, FITZGERALD O, VAN DEN BERG WB, BRESNIHAN B: Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-67.
52. JENKINS JJ, HARDY KJ, MCMURRAY RW: The pathogenesis of rheumatoid arthritis: A guide to therapy. Am J Med Sci 2002; 323: 171-80.
53. DAVIS LS: A question of transformation. The synovial fibroblast in rheumatoid arthritis. Am J Pathol 2003; 162: 1399-402.
54. ASAHARA H, FUJISAWA K, KOBATA T et al.: Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997; 40:912-18.
55. TAK PP, GERLAG DM, AUPPERLE KR et al.: Inhibitor of nuclear factor κB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897-1907.
56. PAP T, AUPPERLE KR, GAY S, FIRESTEIN GS, GAY RE: Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum 2001; 44: 676-81.
57. YAMANISHI Y, BOYLE DL, PINKOSKI MJ et al.: Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002; 160: 123-30.
58. MICCADEI S, PULSELLI R, FLORIDI A: Effect of ionidamine and rhein on the phosphorylation potential generated by respiring rat liver mitochondria. Anticancer Res 1993; 13: 1507-10.
59. CASTIGLIONE S, FANCIULLI M, BRUNO T et al.: Rhein inhibits glucose uptake in Ehrlich ascites tumor cells by alteration of membrane-associated functions. Anticancer Drugs 1993; 4: 407-14.
60. DELPINO A, PAGGI MG, GENTILE PF et al.: Protein synthetic activity and adenylate energy charge in Rhein-treated cultured human glioma cells. Cancer Biochem Biophys 1992; 12: 241-52.